San Dimas, CALIFORNIA3 Active Studies

Ankylosing Spondylitis Clinical Trials in San Dimas, CALIFORNIA

Find 3 actively recruiting ankylosing spondylitis clinical trials in San Dimas, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
1,112
Enrolling

Recruiting Ankylosing Spondylitis Studies in San Dimas

About Ankylosing Spondylitis Clinical Trials in San Dimas

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 3 ankylosing spondylitis clinical trials recruiting participants in San Dimas, CALIFORNIA. These studies are seeking a combined 1,112 participants. Research is being sponsored by Novo Nordisk A/S, Boehringer Ingelheim, AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in San Dimas — FAQ

Are there ankylosing spondylitis clinical trials in San Dimas?

Yes, there are 3 ankylosing spondylitis clinical trials currently recruiting in San Dimas, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Dimas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Dimas research site will contact you about next steps.

Are clinical trials in San Dimas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Dimas studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 3 active trials in San Dimas are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated March 2, 2026 from ClinicalTrials.gov